Ghada A Abusin
Associate Professor of Pediatrics
Vice Chair of IRBMED
Pediatrics
1500 E. Medical Center Drive - MPB-D4212
Ann Arbor, Michigan 48109
[email protected]

Available to mentor
Ghada A Abusin
Clinical Associate Professor
  • About
  • Qualifications
  • Research Overview
  • Recent Publications
    • About

    As a clinician-scholar, I am interested in reporting complicated and unique cases, as well as biomarkers and supportive care algorithms and protocols that assist clinicians with timely decision making. My current scholarly activities are focused on bone marrow transplant (BMT) for hemoglobinopathies.

    Qualifications
    • Fellow
      University of Iowa Children’s Hospital, Pediatrics, 2011
    • Visiting Physician
      University of Washington, Pediatric Bone Marrow Transplant Program at Seattle Cancer Care Alliance, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center,, 2011
    • Pediatric Redisent
      Newark Beth Israel Medical Center, Pediatrics, 2008
    • Senior House-officer
      Rashid Hospital, Internal Medicine, 2004
    • House-officer
      Ministry of Health- University of Khartoum Teaching Hospitals, University of Khartoum, Khartoum, 2003
    • Certificate- Diplome
      University of Iowa, Iowa City, 2014
    • MS
      University of Iowa, Iowa City, 2011
    • Certificate
      University of Iowa, Iowa City, 2011
    • MB BS
      University of Khartoum, Khartoum, 2001
    Research Overview

    Pediatric blood and marrow transplant for non-malignant RBC disorders including hemoglobinopathies and rare congenital anemia.

    Recent Publications See All Publications
    • Additional Scholarship
      An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
      Abusin G. 2021 Nov 19;
    • Additional Scholarship
      An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
      Abusin G. 2021 Nov 19;
    • Additional Scholarship
      A Phase 2/3, Double-Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
      Abusin G. 2021 Oct 23;
    • Additional Scholarship
      A Phase 2/3, Double-Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
      Abusin G. 2021 Oct 23;
    • Additional Scholarship
      A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises
      Abusin G. 2021 Aug 25;
    • Additional Scholarship
      A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises
      Abusin G. 2021 Aug 25;
    • Additional Scholarship
      A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises
      Abusin G. 2021 Aug 24;
    • Additional Scholarship
      A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises
      Abusin G. 2021 Aug 24;